HC Wainwright Estimates Arvinas’ Q1 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Arvinas in a research note issued on Thursday, November 6th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.70) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Arvinas’ Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.74) EPS and Q4 2026 earnings at ($0.71) EPS.

ARVN has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Arvinas in a report on Wednesday, October 8th. BTIG Research upped their target price on shares of Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Piper Sandler reiterated an “overweight” rating and issued a $16.00 target price on shares of Arvinas in a research report on Tuesday, October 7th. Guggenheim lowered their price target on shares of Arvinas from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Finally, Stephens decreased their target price on shares of Arvinas from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Thursday, September 18th. Eleven analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $16.34.

Arvinas Stock Up 6.3%

NASDAQ:ARVN opened at $10.63 on Friday. The stock has a market capitalization of $682.66 million, a PE ratio of -13.12 and a beta of 2.38. The stock’s 50-day moving average price is $8.83 and its 200-day moving average price is $7.91. Arvinas has a 52 week low of $5.90 and a 52 week high of $28.70.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.27. The business had revenue of $41.90 million for the quarter, compared to the consensus estimate of $29.36 million. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.77%. The business’s revenue for the quarter was down 59.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.68) EPS.

Institutional Trading of Arvinas

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd lifted its position in Arvinas by 965.4% in the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company’s stock valued at $33,000 after buying an additional 4,219 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after acquiring an additional 4,835 shares during the period. Canada Pension Plan Investment Board lifted its holdings in shares of Arvinas by 109.4% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after acquiring an additional 3,500 shares during the last quarter. CWM LLC boosted its position in shares of Arvinas by 2,317.5% during the 1st quarter. CWM LLC now owns 7,615 shares of the company’s stock worth $53,000 after purchasing an additional 7,300 shares during the period. Finally, State of Wyoming acquired a new stake in Arvinas in the 3rd quarter valued at approximately $68,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Arvinas

In other Arvinas news, Director Briggs Morrison acquired 30,000 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were purchased at an average cost of $7.57 per share, for a total transaction of $227,100.00. Following the completion of the acquisition, the director owned 76,021 shares of the company’s stock, valued at approximately $575,478.97. The trade was a 65.19% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 4.73% of the company’s stock.

Arvinas announced that its Board of Directors has initiated a share repurchase plan on Wednesday, September 17th that permits the company to repurchase $100.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 17.9% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.